Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance

More than one half melanoma patients have BRAF gene mutation. BRAF inhibitor vemurafenib is an effective medication for these patients. However, acquired resistance is generally inevitable, the mechanisms of which are not fully understood. Cell senescence and senescence-associated secretory phenotyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jianyu, Lin, Zijun, Chen, Weichun, Ruan, Jie, Deng, Fan, Yao, Lin, Rao, Minla, Xiong, Xingdong, Xu, Shun, Zhang, Xiangning, Liu, Xinguang, Sun, Xuerong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345356/
https://www.ncbi.nlm.nih.gov/pubmed/37456058
http://dx.doi.org/10.1016/j.heliyon.2023.e17714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345356/
https://www.ncbi.nlm.nih.gov/pubmed/37456058
http://dx.doi.org/10.1016/j.heliyon.2023.e17714

Ejemplares similares